--- title: "BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)" type: "News" locale: "en" url: "https://longbridge.com/en/news/282747687.md" description: "BioNexus Gene Lab reported a fiscal-year revenue of $7.42 million, a 21.9% decline year-over-year, with a net loss per share of $(1.61). The company faced an 88% increase in operating losses, totaling $(2.965) million. Gross profit was $1.085 million, improving gross margin to 14.7%. Key highlights include a shift in revenue channels, expansion into diagnostics, and a new Ethereum-focused treasury strategy. The company is addressing governance issues at Chemrex and has partnered with ML Tech for digital asset integration." datetime: "2026-04-14T21:25:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282747687.md) - [en](https://longbridge.com/en/news/282747687.md) - [zh-HK](https://longbridge.com/zh-HK/news/282747687.md) generator: "portal-rs" --- # BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61) BioNexus Gene Lab reported fiscal-year revenue of $7.42 million and a net loss per share of $(1.607), reflecting a 21.9% decline in revenue driven by lower Chemrex volume and foreign exchange translation and a wider operating loss. The company recorded a net loss attributable to common shareholders of $(2.985) million on operating losses that increased 88% year-over-year. Gross profit was $1.085 million with a modest improvement in gross margin to 14.7%. **Financial Highlights** - **Revenue**: $7.42 million, decreased 21.9% year-over-year due to lower Chemrex volume and FX translation. - **Gross Profit**: $1.085 million (gross margin 14.7% in 2025 vs 13.7% in 2024). - **Loss from Operations**: $(2.965) million; operating loss increased 88% year-over-year. - **Net Loss Attributable to Common Shareholders**: $(2.985) million, versus $(1.598) million in the prior year. - **Earnings per Share — Basic and Diluted**: $(1.607); weighted average shares outstanding 1,856,680. **Business Highlights** - **Revenue Trend**: Revenue declined roughly 22% year-over-year, primarily from reduced Chemrex sales volume following management changes. - **Channel & Mix Shift**: Chemrex remained the dominant channel (~99.7% of revenue); an improved product mix contributed to a slight uptick in gross margin. - **Diagnostics and Strategic Moves**: Expanded into diagnostics via a Fidelion license and announced plans to advance VitaGuard™ MRD in Southeast Asia through a contemplated 15% equity stake. - **Operational Remediation**: An audit identified governance and control lapses at Chemrex; remediation actions include updated approval workflows and a claims assessment process. - **Digital Treasury & Partnerships**: Announced an Ethereum-focused treasury strategy and a partnership with ML Tech to integrate digital asset and AI capabilities into operations. Original SEC Filing: BioNexus Gene Lab Corp \[ BGLC \] - 10-K - Apr. 14, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [ETHE.US](https://longbridge.com/en/quote/ETHE.US.md) - [BGLC.US](https://longbridge.com/en/quote/BGLC.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ETHA.US](https://longbridge.com/en/quote/ETHA.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [EZET.US](https://longbridge.com/en/quote/EZET.US.md) - [ETHV.US](https://longbridge.com/en/quote/ETHV.US.md) - [ETH.US](https://longbridge.com/en/quote/ETH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ETHW.US](https://longbridge.com/en/quote/ETHW.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [CETH.US](https://longbridge.com/en/quote/CETH.US.md) - [EETH.US](https://longbridge.com/en/quote/EETH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [QETH.US](https://longbridge.com/en/quote/QETH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FETH.US](https://longbridge.com/en/quote/FETH.US.md) ## Related News & Research - [Mapping the Market: Cryptocurrency ether's technical picture brightens after sharp rebound](https://longbridge.com/en/news/296767860.md) - [Tom Lee Sees ETH 'Easily' Hitting $10,000, Says BitMine Could Buy More Than 5%](https://longbridge.com/en/news/296958709.md) - [Aligned Launches $ALIGN, the Native Token of Its Full Ethereum Stack](https://longbridge.com/en/news/296619468.md) - [Ledger Ethereum App Version 1.22.2 Fixes Bug That Could Replace Transactions During Clear Signing](https://longbridge.com/en/news/296882199.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**